2013
DOI: 10.1055/s-0033-1348763
|View full text |Cite
|
Sign up to set email alerts
|

Rotenoids from Mirabilis multiflora

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
3
0

Year Published

2021
2021
2021
2021

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(3 citation statements)
references
References 0 publications
0
3
0
Order By: Relevance
“…Primary screening of rotenoids from M. multiflora was conducted at a final concentration of 10 μM for competitive binding to the corresponding receptor using the reported methodology. For the cannabinoid subtype receptor assays, rotenoids were added into a 96-well plate loaded with CHO-K1 cells, followed by 0.6 nM [ 3 H]-CP-55,940 and 10 μg of a cannabinoid membrane resuspended in 50 mM Tris (pH 7.4), 154 mM NaCl, and 20 mM Di-Na-EDTA supplemented with 0.02% BSA. Saturation experiments were performed to determine the optimal radioligand ([ 3 H]-enkephlin and [ 3 H]-DAMGO) and membrane concentrations for the opioid receptor subtype assays.…”
Section: Methodsmentioning
confidence: 99%
See 2 more Smart Citations
“…Primary screening of rotenoids from M. multiflora was conducted at a final concentration of 10 μM for competitive binding to the corresponding receptor using the reported methodology. For the cannabinoid subtype receptor assays, rotenoids were added into a 96-well plate loaded with CHO-K1 cells, followed by 0.6 nM [ 3 H]-CP-55,940 and 10 μg of a cannabinoid membrane resuspended in 50 mM Tris (pH 7.4), 154 mM NaCl, and 20 mM Di-Na-EDTA supplemented with 0.02% BSA. Saturation experiments were performed to determine the optimal radioligand ([ 3 H]-enkephlin and [ 3 H]-DAMGO) and membrane concentrations for the opioid receptor subtype assays.…”
Section: Methodsmentioning
confidence: 99%
“…348 nm, reminiscent of a (6a S ,12a R ) absolute configuration. Based on the above spectroscopic data, the structure of multiferone B ( 7 ) was assigned unequivocally as (6 R ,6a S ,12a R )-11,12a-dihydroxy-4,6,9-trimethoxy-10-methylrotenone (Figure ). This compound was described by us in 2013, but without defining its absolute configuration and reporting its physical data. These issues have been fully addressed herein.…”
mentioning
confidence: 99%
See 1 more Smart Citation